Barclays (LON:BARC) analyst Steven Valiquette maintained a Buy rating on Mckesson Corp . on Wednesday, setting a price target of $233, which is approximately 23.98% above the present share price of $187.94.
Valiquette expects Mckesson Corp. to post earnings per share (EPS) of -$39.03 for the second quarter of 2021.
The current consensus among 11 TipRanks analysts is for a Moderate Buy rating of shares in McKesson, with an average price target of $219.3.
The analysts price targets range from a high of $235 to a low of $190.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $62.6 billion and a net profit of $860 million. The company's market cap is $29.91 billion.
According to TipRanks.com, Barclays analyst Steven Valiquette is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 3.0% and a 57.43% success rate.
Incorporated in 1833, Texas-based McKesson Corp (NYSE:MCK). provides pharmaceuticals, health information technology, medical supplies, and care management tools. The company operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions, International, and Medical-Surgical Solutions.